Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

NNC 55-0396, a T-type calcium channel blocker, protects against the brain injury induced by middle cerebral artery occlusion and reperfusion in mice.

Matsuda S, Nishikawa H, Fukatsu A, Kurokawa Y, Tsubota M, Sekiguchi F, Tokuyama S, Kawabata A.

J Pharmacol Sci. 2019 Jun;140(2):193-196. doi: 10.1016/j.jphs.2019.02.002. Epub 2019 Feb 21.

2.

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment.

Samukawa Y, Haneda M, Seino Y, Sasaki T, Fukatsu A, Kubo Y, Sato Y, Sakai S.

Clin Pharmacol Drug Dev. 2018 Nov;7(8):820-828. doi: 10.1002/cpdd.456. Epub 2018 Apr 25.

3.

Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.

Seino Y, Sasaki T, Fukatsu A, Imazeki H, Ochiai H, Sakai S.

Curr Med Res Opin. 2018 Jun;34(6):981-994. doi: 10.1080/03007995.2018.1441816. Epub 2018 Mar 20.

PMID:
29448833
4.

A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting.

Tanaka I, Kawada K, Morise M, Hase T, Hayashi H, Sokai A, Fukatsu A, Kondo M, Nomura F, Hasegawa Y.

Cancer Chemother Pharmacol. 2018 Feb;81(2):339-345. doi: 10.1007/s00280-017-3497-0. Epub 2017 Dec 12.

PMID:
29234921
6.

Hybrid Catalysis Enabling Room-Temperature Hydrogen Gas Release from N-Heterocycles and Tetrahydronaphthalenes.

Kato S, Saga Y, Kojima M, Fuse H, Matsunaga S, Fukatsu A, Kondo M, Masaoka S, Kanai M.

J Am Chem Soc. 2017 Feb 15;139(6):2204-2207. doi: 10.1021/jacs.7b00253. Epub 2017 Feb 6.

PMID:
28139917
7.

Conditional Deletion of Smad1 Ameliorates Glomerular Injury in Progressive Glomerulonephritis.

Araki M, Matsubara T, Abe H, Torikoshi K, Mima A, Iehara N, Fukatsu A, Kita T, Arai H, Doi T.

Sci Rep. 2016 Aug 5;6:31216. doi: 10.1038/srep31216.

8.

Identification of MMP1 as a novel risk factor for intracranial aneurysms in ADPKD using iPSC models.

Ameku T, Taura D, Sone M, Numata T, Nakamura M, Shiota F, Toyoda T, Matsui S, Araoka T, Yasuno T, Mae S, Kobayashi H, Kondo N, Kitaoka F, Amano N, Arai S, Ichisaka T, Matsuura N, Inoue S, Yamamoto T, Takahashi K, Asaka I, Yamada Y, Ubara Y, Muso E, Fukatsu A, Watanabe A, Sato Y, Nakahata T, Mori Y, Koizumi A, Nakao K, Yamanaka S, Osafune K.

Sci Rep. 2016 Jul 15;6:30013. doi: 10.1038/srep30013.

9.

YACHIYO HOSPITAL; Center of SUPER CARE MIX--Comprehensive Care from Emergency to Home for the community.

Matsumoto T, Iyomasa S, Fukatsu A.

World Hosp Health Serv. 2016;52(1):11-3.

PMID:
27180467
10.

Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.

Sakai S, Kaku K, Seino Y, Inagaki N, Haneda M, Sasaki T, Fukatsu A, Kakiuchi H, Samukawa Y.

Clin Ther. 2016 Apr;38(4):843-862.e9. doi: 10.1016/j.clinthera.2016.01.017. Epub 2016 Mar 25.

11.

Adjusting the 17β-Estradiol-to-Androgen Ratio Ameliorates Diabetic Nephropathy.

Inada A, Inada O, Fujii NL, Nagafuchi S, Katsuta H, Yasunami Y, Matsubara T, Arai H, Fukatsu A, Nabeshima YI.

J Am Soc Nephrol. 2016 Oct;27(10):3035-3050. Epub 2016 Mar 3. Erratum in: J Am Soc Nephrol. 2017 Feb;28(2):716.

12.

ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage.

Kuragano T, Kitamura K, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, Fujimoto S, Hase H, Joki N, Fukatsu A, Inoue T, Itakura Y, Nakanishi T.

PLoS One. 2016 Mar 2;11(3):e0147328. doi: 10.1371/journal.pone.0147328. eCollection 2016.

13.

The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation.

Kato M, Tsuzuki T, Kimura K, Hirakawa A, Kinoshita F, Sassa N, Ishida R, Fukatsu A, Kimura T, Funahashi Y, Matsukawa Y, Hattori R, Gotoh M.

Mod Pathol. 2016 Feb;29(2):166-73. doi: 10.1038/modpathol.2015.146. Epub 2016 Jan 8.

14.

Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.

Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A, Kakiuchi H, Sato Y, Sakai S, Samukawa Y.

Clin Ther. 2016 Jan 1;38(1):66-88.e20. doi: 10.1016/j.clinthera.2015.10.025. Epub 2015 Dec 22.

15.

Corrigendum.

Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y.

Curr Med Res Opin. 2015 Dec;31(12):2345. doi: 10.1185/03007995.2015.1093404. Epub 2015 Sep 22. No abstract available.

PMID:
26393294
16.

Molecular Markers of Tubulointerstitial Fibrosis and Tubular Cell Damage in Patients with Chronic Kidney Disease.

Nakagawa S, Nishihara K, Miyata H, Shinke H, Tomita E, Kajiwara M, Matsubara T, Iehara N, Igarashi Y, Yamada H, Fukatsu A, Yanagita M, Matsubara K, Masuda S.

PLoS One. 2015 Aug 28;10(8):e0136994. doi: 10.1371/journal.pone.0136994. eCollection 2015.

17.

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus.

Seino Y, Inagaki N, Haneda M, Kaku K, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y.

J Diabetes Investig. 2015 Jul;6(4):443-53. doi: 10.1111/jdi.12316. Epub 2015 Jan 10.

18.

The Authors Reply.

Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, Kitamura K, Fujimoto S, Hase H, Joki N, Fukatsu A, Inoue T, Itakura Y, Nakanishi T.

Kidney Int. 2015 Jul;88(1):197-8. doi: 10.1038/ki.2015.129. No abstract available.

PMID:
26126097
19.

Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.

Sasaki T, Seino Y, Fukatsu A, Ubukata M, Sakai S, Samukawa Y.

Adv Ther. 2015 May;32(5):404-17. doi: 10.1007/s12325-015-0209-1. Epub 2015 May 15.

20.

Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Seino Y, Kaku K, Inagaki N, Haneda M, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y.

Endocr J. 2015;62(7):593-603. doi: 10.1507/endocrj.EJ15-0097. Epub 2015 May 12.

21.

The authors reply.

Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, Kitamura K, Fujimoto S, Hase H, Joki N, Fukatsu A, Inoue T, Itakura Y, Nakanishi T.

Kidney Int. 2015 May;87(5):1075-6. doi: 10.1038/ki.2015.47. No abstract available.

PMID:
25951072
22.

Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.

Sasaki T, Seino Y, Fukatsu A, Ubukata M, Sakai S, Samukawa Y.

Adv Ther. 2015 Apr;32(4):319-40. doi: 10.1007/s12325-015-0200-x. Epub 2015 Apr 9.

23.

Mineral Metabolism Markers Are Associated with Myocardial Infarction and Hemorrhagic Stroke but Not Ischemic Stroke in Hemodialysis Patients: A Longitudinal Study.

Tagawa M, Hamano T, Nishi H, Tsuchida K, Hanafusa N, Fukatsu A, Iseki K, Tsubakihara Y.

PLoS One. 2014 Dec 10;9(12):e114678. doi: 10.1371/journal.pone.0114678. eCollection 2014.

24.

Electrochemical response of metal complexes in homogeneous solution under photoirradiation.

Fukatsu A, Kondo M, Okamura M, Yoshida M, Masaoka S.

Sci Rep. 2014 Jun 17;4:5327. doi: 10.1038/srep05327.

25.

Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients.

Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, Kitamura K, Fujimoto S, Hase H, Joki N, Fukatsu A, Inoue T, Itakura I, Nakanishi T.

Kidney Int. 2014 Oct;86(4):845-54. doi: 10.1038/ki.2014.114. Epub 2014 Apr 23.

26.

Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.

Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y.

Curr Med Res Opin. 2014 Jul;30(7):1245-55. doi: 10.1185/03007995.2014.912983. Epub 2014 Apr 29.

PMID:
24708292
27.

Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study.

Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y.

Curr Med Res Opin. 2014 Jul;30(7):1231-44. doi: 10.1185/03007995.2014.909390. Epub 2014 Apr 15. Erratum in: Curr Med Res Opin. 2015 Dec;31(12):2345.

PMID:
24673496
28.

A new treatment for retroperitoneal fibrosis: initial experiences of using Seprafilm® to wrap the ureter.

Kamihira O, Hirabayashi T, Yamaguchi A, Hirabayashi H, Moriya Y, Fukatsu A, Yoshikawa Y, Matsuura O, Kimura K.

BJU Int. 2014 Oct;114(4):563-7. doi: 10.1111/bju.12701.

29.

Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study.

Seino Y, Sasaki T, Fukatsu A, Sakai S, Samukawa Y.

Curr Med Res Opin. 2014 Jul;30(7):1219-30. doi: 10.1185/03007995.2014.901943. Epub 2014 Mar 19.

PMID:
24597840
30.

Twisted gastrulation, a BMP antagonist, exacerbates podocyte injury.

Yamada S, Nakamura J, Asada M, Takase M, Matsusaka T, Iguchi T, Yamada R, Tanaka M, Higashi AY, Okuda T, Asada N, Fukatsu A, Kawachi H, Graf D, Muso E, Kita T, Kimura T, Pastan I, Economides AN, Yanagita M.

PLoS One. 2014 Feb 25;9(2):e89135. doi: 10.1371/journal.pone.0089135. eCollection 2014.

31.

Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.

Sasaki T, Seino Y, Fukatsu A, Sakai S, Samukawa Y.

Adv Ther. 2014 Mar;31(3):345-61. doi: 10.1007/s12325-014-0102-3. Epub 2014 Feb 18.

32.

LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade.

Tanaka I, Osada H, Fujii M, Fukatsu A, Hida T, Horio Y, Kondo Y, Sato A, Hasegawa Y, Tsujimura T, Sekido Y.

Oncogene. 2015 Jan 2;34(1):73-83. doi: 10.1038/onc.2013.528. Epub 2013 Dec 16.

PMID:
24336325
33.

Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.

Tsuzuki T, Sassa N, Shimoyama Y, Morikawa T, Shiroki R, Kuroda M, Fukatsu A, Kuwahara K, Yoshino Y, Hattori R, Gotoh M.

Histopathology. 2014 Mar;64(4):484-93. doi: 10.1111/his.12277. Epub 2013 Nov 26.

PMID:
24274732
34.

RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer.

Fukatsu A, Ishiguro F, Tanaka I, Kudo T, Nakagawa K, Shinjo K, Kondo Y, Fujii M, Hasegawa Y, Tomizawa K, Mitsudomi T, Osada H, Hata Y, Sekido Y.

Lung Cancer. 2014 Jan;83(1):23-9. doi: 10.1016/j.lungcan.2013.10.014. Epub 2013 Oct 31.

PMID:
24246507
35.

Growth pattern, an important pathologic prognostic parameter for clear cell renal cell carcinoma.

Fukatsu A, Tsuzuki T, Sassa N, Nishikimi T, Kimura T, Majima T, Yoshino Y, Hattori R, Gotoh M.

Am J Clin Pathol. 2013 Oct;140(4):500-5. doi: 10.1309/AJCPIMPE6ZFT8AME.

PMID:
24045546
36.

Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010.

Sugiyama H, Yokoyama H, Sato H, Saito T, Kohda Y, Nishi S, Tsuruya K, Kiyomoto H, Iida H, Sasaki T, Higuchi M, Hattori M, Oka K, Kagami S, Kawamura T, Takeda T, Hataya H, Fukasawa Y, Fukatsu A, Morozumi K, Yoshikawa N, Shimizu A, Kitamura H, Yuzawa Y, Matsuo S, Kiyohara Y, Joh K, Nagata M, Taguchi T, Makino H; Committee for Standardization of Renal Pathological Diagnosis; Committee for Kidney Disease Registry; Japanese Society of Nephrology.

Clin Exp Nephrol. 2013 Apr;17(2):155-73. doi: 10.1007/s10157-012-0746-8. Epub 2013 Feb 6.

PMID:
23385776
37.

Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR).

Yokoyama H, Sugiyama H, Sato H, Taguchi T, Nagata M, Matsuo S, Makino H, Watanabe T, Saito T, Kiyohara Y, Nishi S, Iida H, Morozumi K, Fukatsu A, Sasaki T, Tsuruya K, Kohda Y, Higuchi M, Kiyomoto H, Goto S, Hattori M, Hataya H, Kagami S, Yoshikawa N, Fukasawa Y, Ueda Y, Kitamura H, Shimizu A, Oka K, Nakagawa N, Ito T, Uchida S, Furuichi K, Nakaya I, Umemura S, Hiromura K, Yoshimura M, Hirawa N, Shigematsu T, Fukagawa M, Hiramatsu M, Terada Y, Uemura O, Kawata T, Matsunaga A, Kuroki A, Mori Y, Mitsuiki K, Yoshida H; Committee for the Standardization of Renal Pathological Diagnosis and for Renal Biopsy and Disease Registry of the Japanese Society of Nephrology, and the Progressive Renal Disease Research of the Ministry of Health, Labour and Welfare of Japan.

Clin Exp Nephrol. 2012 Dec;16(6):903-20. doi: 10.1007/s10157-012-0673-8. Epub 2012 Oct 11.

PMID:
23053590
38.

Protein inhibitor of activated STAT, PIASy regulates α-smooth muscle actin expression by interacting with E12 in mesangial cells.

Torikoshi K, Abe H, Matsubara T, Hirano T, Ohshima T, Murakami T, Araki M, Mima A, Iehara N, Fukatsu A, Kita T, Arai H, Doi T.

PLoS One. 2012;7(7):e41186. doi: 10.1371/journal.pone.0041186. Epub 2012 Jul 19.

39.

Is pT3 urothelial carcinoma of the renal pelvis a homogeneous disease entity? Proposal for a new subcategory of the pT3 classification.

Sassa N, Tsuzuki T, Fukatsu A, Majima T, Kimura T, Nishikimi T, Yoshino Y, Hattori R, Gotoh M.

Histopathology. 2012 Oct;61(4):620-8. doi: 10.1111/j.1365-2559.2012.04183.x.

PMID:
22730905
40.

Low density lipoprotein apheresis ameliorates interferon-γ production in patients with nephrotic syndrome.

Miyata H, Uno K, Ono T, Yashiro M, Fukatsu A, Kita T, Kimura T, Muso E.

Ther Apher Dial. 2012 Apr;16(2):189-94. doi: 10.1111/j.1744-9987.2011.01045.x. Epub 2012 Feb 27.

PMID:
22458400
41.

Antibody-mediated rejection of a unilateral donor lung in bilateral living-donor lobar lung transplantation: report of a case.

Chen F, Chibana N, Kanematsu A, Takakura S, Yurugi K, Hishida R, Fukatsu A, Kubo T, Shoji T, Fujinaga T, Bando T, Date H.

Surg Today. 2012 Aug;42(8):808-11. doi: 10.1007/s00595-012-0151-7. Epub 2012 Feb 28.

PMID:
22370964
42.

Involvement of ERK in NMDA receptor-independent cortical neurotoxicity of hydrogen sulfide.

Kurokawa Y, Sekiguchi F, Kubo S, Yamasaki Y, Matsuda S, Okamoto Y, Sekimoto T, Fukatsu A, Nishikawa H, Kume T, Fukushima N, Akaike A, Kawabata A.

Biochem Biophys Res Commun. 2011 Nov 4;414(4):727-32. doi: 10.1016/j.bbrc.2011.09.144. Epub 2011 Oct 6.

PMID:
22001931
43.

Serial renal biopsy findings in a case of POEMS syndrome with recurrent acute renal failure.

Higashi AY, Nogaki F, Kato I, Ono T, Fukatsu A.

Clin Exp Nephrol. 2012 Feb;16(1):173-9. doi: 10.1007/s10157-011-0540-z. Epub 2011 Oct 8.

PMID:
21979795
44.

Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice.

Asada N, Takase M, Nakamura J, Oguchi A, Asada M, Suzuki N, Yamamura K, Nagoshi N, Shibata S, Rao TN, Fehling HJ, Fukatsu A, Minegishi N, Kita T, Kimura T, Okano H, Yamamoto M, Yanagita M.

J Clin Invest. 2011 Oct;121(10):3981-90. doi: 10.1172/JCI57301. Epub 2011 Sep 12.

45.

Comparison of the psychosocial quality of life in hemodialysis patients between the elderly and non-elderly using a visual analogue scale: the importance of appetite and depressive mood.

Kanamori H, Nagai K, Matsubara T, Mima A, Yanagita M, Iehara N, Takechi H, Fujimaki K, Usami K, Fukatsu A, Kita T, Matsubayashi K, Arai H.

Geriatr Gerontol Int. 2012 Jan;12(1):65-71. doi: 10.1111/j.1447-0594.2011.00731.x. Epub 2011 Aug 15.

PMID:
21843200
46.

[IV. Others: 3. Hypokalemia or hypercalcemia-induced renal injuries].

Matsubara T, Iehara N, Fukatsu A.

Nihon Naika Gakkai Zasshi. 2011 May 10;100(5):1313-8. Japanese. No abstract available.

PMID:
21710704
47.

An autopsy case of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) with intestinal bleeding in chronic renal failure.

Mima A, Shiota F, Matsubara T, Iehara N, Akagi T, Abe H, Nagai K, Matsuura M, Murakami T, Kishi S, Araoka T, Kishi F, Kondo N, Shigeta R, Yoshikawa K, Kita T, Doi T, Fukatsu A.

Ren Fail. 2011;33(6):622-5. doi: 10.3109/0886022X.2011.585730. Epub 2011 Jun 1.

PMID:
21631236
48.

Durable hematological response and improvement of nephrotic syndrome on thalidomide therapy in a patient with refractory light chain deposition disease.

Fujita H, Hishizawa M, Sakamoto S, Kondo T, Kadowaki N, Ishikawa T, Itoh J, Fukatsu A, Uchiyama T, Takaori-Kondo A.

Int J Hematol. 2011 May;93(5):673-676. doi: 10.1007/s12185-011-0829-4. Epub 2011 Apr 9.

PMID:
21479586
49.

Nutrition assessment as a predictor of clinical outcomes for infants with cardiac surgery: using the prognostic nutritional index.

Wakita M, Fukatsu A, Amagai T.

Nutr Clin Pract. 2011 Apr;26(2):192-8. doi: 10.1177/0884533611399922.

PMID:
21447774
50.

Activation of Src mediates PDGF-induced Smad1 phosphorylation and contributes to the progression of glomerulosclerosis in glomerulonephritis.

Mima A, Abe H, Nagai K, Arai H, Matsubara T, Araki M, Torikoshi K, Tominaga T, Iehara N, Fukatsu A, Kita T, Doi T.

PLoS One. 2011 Mar 22;6(3):e17929. doi: 10.1371/journal.pone.0017929.

Supplemental Content

Loading ...
Support Center